We have performed the retrospective comparison of the parameters of physical development (circumference of head and chest, body weight and length), dynamics of laboratory tests, death rate in 103 HIV-positive and 77 HIV-exposed children. The majority of the studied parameters were within the normal range. The differences between the groups revealed in the follow up might be used for HIV status prognosis.

В статье представлен клинический случай редкой патологии - токсоплазменного абсцесса у ВИЧ-инфицированной пациентки, который не был диагностирован при жизни. Учитывая неспецифическое описание картины поражения головного мозга на магнитно-резонансной томографии, заболевание было расценено как лимфома головного мозга. Описаны клинические проявления заболевания и морфологические изменения в пораженных органах. Показана на конкретном примере сложность верификации диагноза крайне редкого осложнения токсоплазменного одиночного очага - абсцесса.

In the article we can determine changes of parameters of the general and biochemical analyses of blood, also me can find clinical displays at patients on the various schemes of antiretroviral therapy applied to treatment of a HIV-infected in the Gomel regional infectious hospital are presented. It is revealed, that at the HIV-infected receiving various schemes of antiretroviral therapy, in 1-6 months of treatment the individual clinically expressed by-effects leading a cancelling or change of the scheme of antiretroviral therapy were observed. On the scheme: combivir + stocrin leading change were registered hematologic changes (heavy anemia) in 11, 8% of cases therefore scheme of therapy was changed. At the patients was on the scheme combivir +virasept, in 1 month from the beginning of treatment the maintenance of the general bilirubin in whey of blood authentically increased. Among the patients received stocrin + epivir + zerit, in 1 month from the beginning of treatment activity α- -amylase authentically increased. At the majority of patients with revealed аnti-HCVtot with presence of biochemical activity on a background of treatment parameters ALT were normalized.

Objective : to evaluate the effectiveness of two interferon (IFN)-based antiviral therapy of chronic hepatitis C (IFN/RBV or PEG-IFN/RBV)depending on HCV genotype, IL-28B gene mutations and to determinethe group of patients who need treatment with direct antiviral agents. Material and methods. The study involved 844 patients with chronic hepatitis C (60.6 % men; 51.9 % with genotype 1 virus) in two infectious diseases hospitals. 324 patients received treatment with standard interferon and ribavirin (IFN/RBV), 520 patients - with pegylated interferon and ribavirin (PEG-IFN/RBV). Polymerase chain reaction was applied to determinesingle nucleotide polymorphisms (SNPs) rs12979860 and rs8099917 of IL-28B gene. Results. The effectiveness (sustained virologic response, SVR) of the scheme IFN/RBV in patients with HCV genotype 1 was 23.9 %, and of PEG-IFN/RBV - 48.4 %. The highest frequency rate of SVR was recorded in patients with CC variant of SNP rs12979860 - 73.3 and 82.1 % (for IFN/RBV and PEG-IFN/RBV schemes, respectively). Schemes IFN/RBV (SVR 70.8 %) and PEG-IFN/RBV (SVR 86.5 %) were highly effective for patients with HCV genotypes 2 and 3. The treatment was not effective in patients with genotype 1 HCV having gene IL-28B SNPs rs12979860 CT or TT and rs8099917 TG or GG and in patientsover 40. Conclusion. It is prospectiveto use non-IFN regimens based on direct-acting antiviral agents to treat patients with 1 HCV genotype with genotype CT/TT (rs12979860) and TG/GG (rs8099917), as well as those who did not respond previously to the antiviral treatment with PEG-IFN/RBV.The implementation of the non-IFN regimens should be accelerated by means of registration or development of production of generic drugs.

The serum levels of cytokines TNF-α, IL-1β, IL-2, IL-4 in 85 patients with chronic hepatitis C with various antibodies spectrum to hepatitis C virus (HCV) and in 42 with different morphological changes in liver tissue were studied. In patients with antiNS5 negative and also antiHCV IgM and antiNS5 HCV both negative, IL-1β levels were significantly higher vs. those patients with these antibodies positive. The cytokines levels increased with raise of histological activity. In patients with sclerosis signs in liver bioptates the levels of investigated cytokines were higher than in healthy blood donors. Significant differences of IL-1β from donors were revealed in patients with various degree of sclerosis. Also the levels of IL-1β, IL-2 and TNF-α were higher in patients with heavy sclerosis degree. The prognostic value for early virologic response of cytokine TNF-α before the beginning of treatment was shown.